The analytical performance of troponin assays has improved markedly in the last 2 decades. The variety of assays, their evolution over time, and their critical importance in influencing care, mandates the need for skills in their use. There are 3 critical elements necessary for optimal use of troponin testing in clinical care, as follows: 1) the analytical performance of the assay; 2) the clinical sensitivity and specificity of the test result; and 3) the clinical reasoning for in Europe, and we anticipate they will be approved in the United States in the near future.
. Improving our understanding of troponin testing is particularly important now because high-sensitivity assays are already in use in Europe, and we anticipate they will be approved in the United States in the near future. 
ANALYTICAL PERFORMANCE OF TROPONIN ASSAYS
Troponin is a protein complex that regulates the excitation and contraction of striated muscle. The troponin complex consists of 3 molecules: troponin C, troponin I, and troponin T, each of which has different functions and are encoded by separate genes (9, 10) . Troponin I and troponin T have amino acid sequences specific to cardiac tissue, making these molecules ideal biological markers (11, 12) . In the late 1980s, investigators developed immunoassays for troponin I and troponin T (13, 14) . Refinements in the antibodies, reagents, and automation have made the current commercial troponin assays exquisitely sensitive and precise (12) . The newest, most sensitive assays are able to detect troponin in the bloodstream of patients without myocardial damage, perhaps due to normal myocardial cell turnover or formation of exosomes that release small amounts of free troponin into the bloodstream (10).
Assay manufacturers measure and report the analytical performance characteristics of each assay.
The analytical sensitivity of the troponin assay is defined by the limit of detection (LOD), which is the lowest concentration of an analyte that is consistently detectable. The precision of the assay is defined by the coefficient of variation (CV). Because the CV is a measurement of the assay's variability relative to the concentration of the analyte, the CV increases at lower concentrations. Ideally the CV of an assay is 10% or less at the level that is chosen as a diagnostic cutpoint. Automated assays performed in central laboratories have better precision and lower 10% CV levels than point-of-care troponin assays (11) .
A point-of-care assay may have a 10% CV level that is an order of magnitude higher than an assay performed in the central laboratory. Point-of-care assays are not used for serial troponin measurements because the imprecision of these assays could
give the misleading appearance of a rise or fall in the troponin level (12) . As the analytical capabilities of troponin testing have improved over the years, the term sensitivity has become a source of confusion for clinicians.
Laboratory experts usually use the word sensitivity to describe the analytical sensitivity, or the ability of an assay to detect low concentrations of an analyte.
Clinicians, in contrast, use the word to describe clinical sensitivity, an operating characteristic of a test that is usually a tradeoff with specificity, as discussed in the next section.
DEFINING THE OPERATING CHARACTERISTICS OF TESTS
For proper interpretation of a test result, clinicians must know the clinical operating characteristics of the test, namely the sensitivity and specificity. The conventional way to characterize a test's operating characteristics is by graphing the range of possible test results for subjects with and without disease, as defined by another gold-standard assessment, as shown in Figure 1 . Where the line is drawn determines the sensitivity and specificity of the test.
Sensitivity and specificity can be confusing terms. for specificity may be less confusing, because these terms are more relevant to practice and the way that the numbers are used. To demonstrate how specificity is the true negative rate and sensitivity is the true positive rate, these rates are shown separately in In addition to the ROC method for determining a cutpoint, another method uses a distribution of test results from a group of subjects who are clearly normal. Typically (and arbitrarily), the inner 95th percentile is used (which is 2 SDs from the mean in a normal distribution), and patients below the 2.5th density on left y-axis) and the TNR and TPR are shown in orange (referring to cumulative probability on the right y-axis of both panels) for a test with a specificity of 80% and a sensitivity of 95% (gray). TNR ¼ true negative rate; TPR ¼ true positive rate. 
Range of Possibilities
The operating characteristics (sensitivity and specificity) of a test, defined among test subjects without disease (left blue curve) and with disease (right blue curve), as defined by another gold-standard test. The line of demarcation divides positive test results (gray) from negative test results (orange).
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CLINICAL SENSITIVITY AND SPECIFICITY OF TROPONIN ASSAYS
When the early troponin assays were developed, it became apparent that the test was superior to other available tests, such as creatine phosphokinase (CK) and CK-MB. The early troponin assay had virtually no false positives from skeletal muscle injury, and when used in a narrowly defined population, it had high sensitivity and specificity for diagnosing acute myocardial infarction (as defined using clinical criteria including CK-MB measurement as the gold standard) (14) . Several subsequent studies, however,
showed that detectable troponin levels below the ROC-determined cutpoint for acute myocardial infarction had prognostic significance (17) (18) (19) . Clinical Almost all patients in a normal population had undetectable troponin levels (the presumed troponin distribution beyond the limit of detection is shown by the dotted curves). The cutpoint, which was defined by an analytical specificity of 99% in a normal population, was so low that it happened also to define a higher clinical sensitivity (further to the left on the x-axis) than the ROC-derived cutpoint.
With each new generation of troponin assay, there have been improvements in the assay's analytical sensitivity and precision. Also, with each new generation, the 99th percentile has been defined in different cohorts of normal test subjects. As a result, the shape of the distribution curves that define the 99th percentile has narrowed, which has moved the 99th percentile cutpoint to the left ( Figure 3 ). The figure shows the distribution, limits of detection, and 99th percentile for second-generation and fourthgeneration troponin T assays. Lowering the 99th percentile cutpoint has adversely affected the clinical specificity of the assays, which led one commentator to remark, "when troponin was a lousy assay it was a great test, but now that it's becoming a great assay, it's getting to be a lousy test" (27) .
Because of the high limits of detection of the early assays, most clinicians have been conditioned to think that any detectable troponin is due to myocardial necrosis or injury. Now, with increasing analytical sensitivity of troponin assays, troponin is detectable in many more normal subjects and in many patients with myocardial necrosis for reasons other than acute myocardial ischemia due to plaque rupture.
Investigators have also examined how the definition of a "normal" population can affect the measurement of troponin and the 99th percentile cutoff.
They have shown that by narrowly defining the population, using questionnaires or preliminary testing by using electrocardiograms, the distribution of normal troponin levels becomes narrower, again Brush, Jr., et al.
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causing the 99th percentile cutoff to shift to the left, as shown in the purple curve in The left panel of Figure 5 shows that the current fourth-generation troponin T assay commonly used in the United States is pushing the limit of a test's analytical capabilities, with the 99th percentile reported at 0.01 mg/l, the limit of detection around the same value, and the level for the 10% CV at 0.03 mg/l. Troponin is a protein complex released into the blood stream when heart tissue is damaged by AMI or other causes (upper left). The troponin complex consists of 3 molecules, troponin C, troponin I, and troponin T, which are bound to actin or free in the cytoplasm of the cardiomyocyte (upper right). Troponin I and troponin T have amino acid sequences that are cardio-specific, making them ideal biomarkers for cardiac injury. The graph shows how troponin levels may be distributed in patients with suspected acute myocardial infarction and subjects in a normal reference group (Ref. Group). Initially, the cutpoint for distinguishing patients with AMI (þAMI) (green curve) from patients without AMI (ÀAMI) (orange curve) was determined using the ROC method, using CK-MB and other clinical criteria as the gold standard. However, clinical trials showed that detectable troponin levels below the ROC-determined cutpoint for AMI had prognostic significance, and unstable angina patients with detectable troponin levels below that point had better outcomes when treated with antithrombotic medications and interventional procedures. Thus, a 1999 consensus panel decided to draw the cutpoint for defining an AMI lower, at the 99th percentile of a normal reference group (blue curve). Most patients in this reference group had troponin levels below the LOD of the early assays (dashed segment of blue curve). The 99th percentile definition and the progressively lower 99th percentile levels of various newer generation troponin assays have created confusion for clinicians who are frequently asked to interpret troponin levels. AMI ¼ acute myocardial infarction; CK-MB ¼ creatine phosphokinase-MB; LOD ¼ limit of detection; ROC ¼ receiver operating characteristic.
Troponin Testing for Clinicians ( Figure 5 , right panel) (12) . Interestingly, the shape of the distribution of troponin levels using the newer high-sensitivity troponin T assay is apparently similar to the presumed shape of the fourth-generation assay because the 99th percentile is essentially the same (0.014 mg/l compared with 0.01 mg/l for the fourth-generation assay). For the newer assays, "high sensitivity" has been defined as an assay that has imprecision of <10% at the level of the 99th percentile and that is able to detect troponin at concentrations that are lower than 50% of the level of the 99th percentile (2,12).
TROPONIN USE IN CURRENT PRACTICE
In practice, the ordering criteria for troponin in 
SPECTRUM BIAS
Using a test in a broad, unselected group of patients can result in a phenomenon known as spectrum bias (29, 30) . Spectrum bias can markedly change the operating characteristics (sensitivity and specificity) of a test from those that were carefully defined in a controlled research setting. As discussed earlier and shown in Figure 4 , the probability curves of a test result become narrower when the definition of a normal population is more narrowly defined. With spectrum bias, the opposite occurs and the probability curve widens. Because the line of demarcation remains fixed, the specificity of the test falls as the curve widens ( Figure 6 ).
To demonstrate the effect of spectrum bias, we can compare the operating characteristics of troponin testing in a research study to the operating characteristics that we may see in practice in a busy ED. In a published study describing the operating characteristics of troponin T (31), the test was used in a strictly defined population of patients presenting with chest 
Range of Possible Troponin Levels Probability Density
Distributions of troponin levels for a normal reference group that is defined with increasingly narrower inclusion criteria, causing the 99th percentile of the distribution of a normal reference group to shift to the left on the x-axis. Brush, Jr., et al. Brush, Jr., et al.
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Troponin Testing for Clinicians 2371 Table 2 Table 2 ). This reduces the specificity (TNR) of the test from 80% (664 of 830) shown in Table 1 to 53% (468 of 884) in Table 2 , whereas the sensitivity (TPR) is slightly reduced from the 95% (162 of 170) shown in Table 1 to 93% (108 of 116) in Table 2 . The right panel of Figure 6 shows how this will affect the separation of our patients with no disease from patients with acute myocardial infarction. The shape of the probability density curve (Figure 7, shown in blue) for the patients with no disease has become wider and shorter, with more overlap with the curve for the patients with acute myocardial infarction, and the specificity ( Figure 7 , TNR, shown in red) has dropped from 80% to 53%. Broadening the inclusion criteria for troponin testing broadened the shape of the probability density curve for the normal population, the opposite of what we saw in Figure 4 , and because the line of demarcation remained fixed, widening the curve markedly decreased the specificity (TNR).
BAYESIAN REASONING
How should a test's clinical sensitivity and specificity affect our thinking about an individual patient? In clinical practice, we generate hypotheses (provisional diagnoses) that might explain a patient's presentation and use iterative hypothesis testing to determine the plausibility of the initial provisional diagnoses.
Bayesian reasoning is a method that enables us to incorporate our original thinking about a patient with a test result to determine the post-test probability of a diagnosis. In clinical medicine we usually estimate the probabilities subjectively and intuitively, using a heuristic (mental process) called anchoring and adjusting (8) . We estimate an initial or prior probability of a diagnosis on the basis of clinical presentation, history of cardiovascular disease or risk factors, and electrocardiographic changes, which becomes the anchor; and then we adjust our initial probability estimate on the basis of the strength of a test result to determine the posterior probability of a diagnosis. If we become too anchored to our prior probability estimate, we commit a fallacy known as anchoring. If we use the test result without considering the prior probability, we commit another fallacy known as base-rate neglect. Experienced clinicians often have an intuitive ability to estimate prior probabilities and appropriately adjust on the basis of an intuitive sense of the strength of a test result.
Likelihood ratios are very useful in this regard because they are a measurement of the strength of Brush, Jr., et al.
the test result (32) . They can help us know how much we should adjust our initial probability estimate as we attempt to determine the final probability estimate. We can multiply a likelihood ratio with the pretest odds to yield the post-test odds of a diagnosis. Or, if we are using the anchoring-and-adjusting heuristic, we can use likelihood ratios to calibrate our intuition, giving us a sense of how much we should adjust our initial probability estimate.
Bayesian reasoning is graphically displayed in Figure 7 . Figure 7 left panel shows how a troponin test with a sensitivity of 95% and a specificity of 80% should shift our thinking. We can choose a prior probability of acute myocardial infarction along the range of possible prior probabilities from 0 to 1 (or 0% to 100%) on the x-axis. We can then draw a vertical line from that point to 1 of the 2 curves (the upper curve for a positive test result and the lower curve for a negative test result), and then draw a horizontal line from the point on the curve to the y-axis to determine the posterior probability of acute myocardial infarction. and a specificity of 53%.
